Expression analysis revealed that MTDH expression is significantly higher in melanoma, breast, esophageal, gastric, hepatocellular, endometrial and prostate cancers, renal cell carcinoma, neuroblasoma and malignant glioma cell lines compared with their normal counterparts [12], [15]–[23]. Here, MTDH is linked to prostate cancer.